[1,2]Oxazolo[4,5-b]pyridin-7-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异恶唑并吡啶类
• 英文名称: [1,2]Oxazolo[4,5-b]pyridin-7-amine
• 英文别名: [1,2]oxazolo[4,5-b]pyridin-7-amine
• 化学式: C₆H₅N₃O
• 分子量: 135.12
• InChiKey: VEFILPQJQRHUBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Heterocyclic inhibitors of MEK and methods of use thereof
  申请人：Wallace Eli

  公开号：US20050153942A1

  公开（公告）日：2005-07-14

  Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R 1 , R 2 , R 7 , R 8 and R 9 , W, X, Y and Z are as defined in the specification. Such compounds are MEK inhibitors and are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

  本发明涉及公式I的化合物及其药学上可接受的盐和前药，其中R1、R2、R7、R8和R9、W、X、Y和Z如规范中所定义。这些化合物是MEK抑制剂，可用于治疗哺乳动物的增殖过度疾病，如癌症和炎症，以及炎症病症。本发明还涉及使用这些化合物治疗哺乳动物的增殖过度疾病的方法和含有这些化合物的制药组合物。
• EP1689406A4
  申请人：——

  公开号：EP1689406A4

  公开（公告）日：2007-01-17
• HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF
  申请人：Array Biopharma, Inc.

  公开号：EP1689406A2

  公开（公告）日：2006-08-16
• US7576072B2
  申请人：——

  公开号：US7576072B2

  公开（公告）日：2009-08-18
• [EN] HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS HETEROCYCLIQUES DE MEK ET METHODES D'UTILISATION ASSOCIEES
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2005051906A2

  公开（公告）日：2005-06-09

  Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X, Y and Z are as defined in the specification. Such compounds are MEK inhibitors and are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.